Structure Therapeutics Inc. (GPCR) Stock Forecast
GPCR analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.62 / 5 from 16 analysts
- Price target
- $105.78 average of analyst targets
- Upside to target
- +401.8% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.51
- 52-week range
- $21.08 – $93.79
GPCR analyst ratings
16 analystsNumber of analysts at each rating.
GPCR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
GPCR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.24 | −$0.57 | $2.02 | −$0.37 | +34.9% | 10 |
| Current fiscal year (2026) | −$1.62 | −$2.04 | $0.94 | −$0.80 | −102.0% | 11 |
| Next fiscal year (2027) | −$2.19 | −$2.53 | −$1.57 | −$1.62 | −35.2% | 9 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
GPCR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $50.0M | $0 | $500.0M | 0.0% | 10 |
| Current fiscal year (2026) | $41.7M | $0 | $500.0M | 0.0% | 12 |
| Next fiscal year (2027) | $45,450 | $0 | $500,000 | −99.9% | 11 |
GPCR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
GPCR revenue: reported and forecast
GPCR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.19 | −$0.19 | −$0.23 | −$0.24 | −$0.24 | +28.9% | 0 up · 1 down |
| Current fiscal year (2026) | −$1.43 | −$1.43 | −$1.62 | −$1.62 | −$1.62 | +13.0% | 0 up · 2 down |
| Next fiscal year (2027) | −$2.08 | −$2.08 | −$2.19 | −$2.19 | −$2.19 | +5.2% | 1 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
GPCR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; GPCR beat in 5 of 12.
What analysts expect from GPCR
16 analysts cover Structure Therapeutics; their consensus rating is strong buy (4.62 on a 1–5 scale, where 5 is a strong buy). The average price target is $105.78, 401.8% above the latest close of $21.08. Analysts expect earnings of −$1.62 per share for 2026, −102.0% from a year earlier. For 2027 the average estimate is −$2.19 per share on revenue of $0.0 million. Structure Therapeutics beat the EPS estimate in 5 of the last 12 quarters.
Related: GPCR income statement, GPCR key metrics, GPCR chart. See the GPCR stock overview for the latest quote and news.
GPCR forecast FAQ
What is Structure Therapeutics's price target?
The average analyst price target for Structure Therapeutics is $105.78, 401.8% above the latest close of $21.08.
Is Structure Therapeutics a buy, hold or sell?
Of 16 analysts covering Structure Therapeutics, 11 rate it a strong buy, 4 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Structure Therapeutics's EPS forecast?
Analysts forecast −$1.62 per share for 2026 (range −$2.04 to $0.94); for 2027 the estimate is −$2.19.
What is Structure Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $41.7 million, growth of 0.0%; for 2027 it is $0.0 million.
When does Structure Therapeutics report earnings?
Structure Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.51.
Does Structure Therapeutics usually beat earnings estimates?
Structure Therapeutics reported EPS at or above the analyst estimate in 5 of the last 12 quarters.